{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:18:06Z","timestamp":1794356286944,"version":"4.9.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karlsruher Institut f\u00fcr Technologie (KIT)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Simultaneous inhibition of DNA gyrase and topoisomerase IV (Topo IV) is a primary pharmacological strategy to enhance antibacterial efficacy and markedly reduce the emergence of antibiotic resistance. In this regard, a new set of twelve ciprofloxacin-based derivatives was rationally developed, synthesized, and structurally verified. The DNA gyrase and Topo IV inhibitory actions of the developed Compounds\n                    <jats:bold>6a-l<\/jats:bold>\n                    were investigated. Compound\n                    <jats:bold>6\u00a0g<\/jats:bold>\n                    showed the most promising results, with IC\n                    <jats:sub>50<\/jats:sub>\n                    values of 1.75\u2009\u00b1\u20090.05 and 03.47\u2009\u00b1\u20090.14 \u00b5M against DNA gyrase and Topo IV, respectively, compared to ciprofloxacin at 02.13\u2009\u00b1\u20090.06 and 25.22\u2009\u00b1\u20091.27 \u00b5M, respectively. Compound\n                    <jats:bold>6\u00a0g<\/jats:bold>\n                    demonstrated the highest antibacterial activity, with MIC values of 0.025, 0.025, and 0.125\u00a0\u00b5g\/mL against\n                    <jats:italic>E. coli<\/jats:italic>\n                    ,\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    , and\n                    <jats:italic>S. aureus<\/jats:italic>\n                    , respectively. It exhibits comparable efficacy to ciprofloxacin against\n                    <jats:italic>E. coli<\/jats:italic>\n                    , a gram-negative bacterium, although it possesses only half the potency against\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    and the gram-positive\n                    <jats:italic>S. aureus<\/jats:italic>\n                    . Compound\n                    <jats:bold>6\u00a0g<\/jats:bold>\n                    exhibits a significant antibiofilm action; at the MIC level, the biofilm inhibition percentage was 96%. Docking analyses revealed that Compound\n                    <jats:bold>6\u00a0g<\/jats:bold>\n                    displays enhanced binding affinity for\n                    <jats:italic>E. coli<\/jats:italic>\n                    DNA gyrase B and Topo IV compared to ciprofloxacin. Molecular dynamics simulations validated the exceptional stability of the\n                    <jats:bold>6\u00a0g<\/jats:bold>\n                    \u2013DNA gyrase B complex. In silico ADMET studies demonstrated satisfactory lipophilicity and metabolic characteristics. These findings collectively underscore\n                    <jats:bold>6\u00a0g<\/jats:bold>\n                    as a viable antibacterial candidate.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-50106-z","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:14:47Z","timestamp":1777554887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design, synthesis, and antibacterial assessment of a new series of ciprofloxacin-based compounds as possible dual DNA gyrase\/topoisomerase IV inhibitors"],"prefix":"10.1038","volume":"16","author":[{"given":"Lamya H.","family":"Al-Wahaibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayat Ali","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Br\u00e4se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa G. M.","family":"Youssif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"6","key":"50106_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2413772","volume":"393","author":"RV Randremanana","year":"2025","unstructured":"Randremanana, R. V. et al. Ciprofloxacin versus aminoglycoside\u2013ciprofloxacin for bubonic plague. N. Engl. J. Med. 393(6), 544\u2013555 (2025).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"50106_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ismeco\/ycaf169","volume":"5","author":"A Hayes","year":"2025","unstructured":"Hayes, A. et al. Common non-antibiotic drugs enhance selection for antimicrobial resistance in mixture with ciprofloxacin. ISME Commun. 5(1), ycaf169 (2025).","journal-title":"ISME Commun."},{"issue":"9","key":"50106_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094919","volume":"25","author":"V Khwaza","year":"2024","unstructured":"Khwaza, V., Mlala, S. & Aderibigbe, B. A. Advancements in synthetic strategies and biological effects of ciprofloxacin derivatives: A review. Int. J. Mol. Sci. 25(9), 4919 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"50106_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.14421\/biomedich.2025.142.873-878","volume":"14","author":"L Savitri","year":"2025","unstructured":"Savitri, L. et al. Effect of ciprofloxacin administration on gastric histopathological changes in mice. Biology, Medicine, & Natural Product Chemistry 14(2), 873\u2013878 (2025).","journal-title":"Biology, Medicine, & Natural Product Chemistry"},{"issue":"4","key":"50106_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.30526\/38.4.3648","volume":"38","author":"TF Ahmed","year":"2025","unstructured":"Ahmed, T. F. & Yahya, N. Z. Evaluation of interaction ciprofloxacin-ascorbic acid against Escherichia coli inducing urinary tract infection in rats. Ibn Al-Haitham J. Pure Appl. Sci. 38(4), 97\u2013106 (2025).","journal-title":"Ibn Al-Haitham J. Pure Appl. Sci."},{"issue":"5","key":"50106_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16050648","volume":"16","author":"VK Panthi","year":"2024","unstructured":"Panthi, V. K., Fairfull-Smith, K. E. & Islam, N. Ciprofloxacin-loaded inhalable formulations against lower respiratory tract infections: challenges, recent advances, and future perspectives. Pharmaceutics 16(5), 648 (2024).","journal-title":"Pharmaceutics"},{"key":"50106_CR7","first-page":"1","volume":"17","author":"X Su","year":"2024","unstructured":"Su, X. et al. Improvement and recovery of intestinal flora disorder caused by ciprofloxacin using lactic acid bacteria. Probiotics Antimicrob. Proteins. 17(6), 1 (2024).","journal-title":"Probiotics Antimicrob. Proteins."},{"issue":"6","key":"50106_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/ph18060800","volume":"18","author":"S Wahood","year":"2025","unstructured":"Wahood, S. et al. Fluoroquinolones for dermatologists: A practical guide to clinical use and risk management. Pharmaceuticals 18(6), 800 (2025).","journal-title":"Pharmaceuticals"},{"issue":"3","key":"50106_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030804","volume":"15","author":"A Rusu","year":"2023","unstructured":"Rusu, A., Munteanu, A.-C., Arb\u0103na\u0219i, E.-M. & Uivarosi, V. Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile?. Pharmaceutics 15(3), 804 (2023).","journal-title":"Pharmaceutics"},{"issue":"3","key":"50106_CR10","first-page":"134","volume":"4","author":"M Samir","year":"2021","unstructured":"Samir, M., Ramadan, M., Hamed, M. & Osman, M. Recent strategies in design of antitumor and antibacterial fluoroquinolones. J. Adv. Biomed. Pharm. Sci. 4(3), 134\u2013151 (2021).","journal-title":"J. Adv. Biomed. Pharm. Sci."},{"issue":"4","key":"50106_CR11","doi-asserted-by":"publisher","first-page":"dlae127","DOI":"10.1093\/jacamr\/dlae127","volume":"6","author":"L Kherroubi","year":"2024","unstructured":"Kherroubi, L., Bacon, J. & Rahman, K. M. Navigating fluoroquinolone resistance in Gram-negative bacteria: A comprehensive evaluation. JAC-Antimicrob. Resist. 6(4), dlae127 (2024).","journal-title":"JAC-Antimicrob. Resist."},{"key":"50106_CR12","doi-asserted-by":"crossref","unstructured":"Iftikhar, H. Redesigning Fluoroquinolones: A Hybrid Strategy to Reduce Cardiotoxicity and Enable Neuroprotective Repurposing, (2025).","DOI":"10.26434\/chemrxiv-2025-9gxb1"},{"key":"50106_CR13","doi-asserted-by":"crossref","unstructured":"Marathe, K. R., Koli, S. H., Patil, A. S. & Patil, S. V. Role of \u03b2-Lactams, \u03b2-Lactamases Inhibitors, and Efflux Pump Inhibitors in the Battle Against Antibiotic Resistance, Antimicrobials in Animal Husbandry pp. 95\u2013123 (CRC, 2026).","DOI":"10.1201\/9781003269847-4"},{"key":"50106_CR14","doi-asserted-by":"crossref","unstructured":"Gupta, D., Sachdeva, E., Salman, M. & Kaur, P. Topoisomerases as targets for halting bacterial DNA replication, Bacterial Enzymes as Targets for Drug Discovery, Elsevier2025, pp. 187\u2013214.","DOI":"10.1016\/B978-0-443-22222-1.00012-X"},{"issue":"3","key":"50106_CR15","first-page":"377","volume":"61","author":"K Drlica","year":"1997","unstructured":"Drlica, K. & Zhao, X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61 (3), 377\u2013392 (1997).","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"11","key":"50106_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/genes10110859","volume":"10","author":"JH Lee","year":"2019","unstructured":"Lee, J. H. & Berger, J. M. Cell cycle-dependent control and roles of DNA topoisomerase II. Genes 10 (11), 859 (2019).","journal-title":"Genes"},{"issue":"1","key":"50106_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/cimb48010067","volume":"48","author":"SN Vasilopoulos","year":"2026","unstructured":"Vasilopoulos, S. N. et al. Replication stress in cancer: Mechanistic insights and therapeutic opportunities for radiosensitization. Curr. Issues Mol. Biol. 48(1), 67 (2026).","journal-title":"Curr. Issues Mol. Biol."},{"key":"50106_CR18","doi-asserted-by":"publisher","DOI":"10.1039\/d5cc06239j","author":"R Mishra","year":"2026","unstructured":"Mishra, R. & Ahmad, S. Protein-DNA interactions in disease and drug discovery. Chem. Commun. https:\/\/doi.org\/10.1039\/d5cc06239j (2026).","journal-title":"Chem. Commun."},{"key":"50106_CR19","unstructured":"Walsh, G. Biopharmaceuticals: biochemistry and biotechnology (Wiley, 2026)."},{"issue":"1","key":"50106_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang, K. et al. Artificial intelligence in drug development. Nat. Med. 31(1), 45\u201359 (2025).","journal-title":"Nat. Med."},{"key":"50106_CR21","first-page":"279","volume-title":"Drug design and discovery: principles and applications","author":"S-F Zhou","year":"2017","unstructured":"Zhou, S.-F. & Zhong, W.-Z. Drug design and discovery: principles and applications 279 (MDPI, 2017)."},{"issue":"5","key":"50106_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/17460441.2025.2490251","volume":"20","author":"L Calzetta","year":"2025","unstructured":"Calzetta, L. et al. Novel drug discovery strategies for chronic obstructive pulmonary disease: The latest developments. Expert Opin. Drug Discov. 20(5), 683\u2013692 (2025).","journal-title":"Expert Opin. Drug Discov."},{"key":"50106_CR23","doi-asserted-by":"crossref","unstructured":"Klebe, G. Optimization of lead structures, Drug Design: From Structure and Mode-of-Action to Rational Design Concepts, Springer2025, pp. 115\u2013126.","DOI":"10.1007\/978-3-662-68998-1_8"},{"issue":"07","key":"50106_CR24","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1142\/S2737416524500881","volume":"25","author":"P Varude","year":"2026","unstructured":"Varude, P. & Satish, D. Integrative computational design of PD-L1 inhibitors, utilizing MD simulations and DFT studies to guide cancer treatment through atomic and electronic properties. J. Comput. Biophys. Chem. 25(07), 1013\u20131031 (2026).","journal-title":"J. Comput. Biophys. Chem."},{"issue":"2","key":"50106_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1021\/acs.jcim.4c00918","volume":"65","author":"S Kumar","year":"2025","unstructured":"Kumar, S. et al. Structure\u2013activity relationship of Ciprofloxacin towards S-Spike Protein of SARS-CoV-2: Synthesis and in-silico evaluation. J. Chem. Inf. Model. 65(2), 825\u2013844 (2025).","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"50106_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11030-024-10862-4","volume":"29","author":"V Sharma","year":"2025","unstructured":"Sharma, V. et al. Quinolone scaffolds as potential drug candidates against infectious microbes: A review. Mol. Divers. 29(1), 711\u2013737 (2025).","journal-title":"Mol. Divers."},{"key":"50106_CR27","doi-asserted-by":"crossref","unstructured":"Gautam, S. K. Comprehensive Review of Recent Advancements and Future Perspectives of Antimicrobials in Animal Husbandry. Antimicrobials Anim. Husb. 228\u2013254. (2026).","DOI":"10.1201\/9781003269847-9"},{"issue":"1","key":"50106_CR28","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1080\/14756366.2021.1931861","volume":"36","author":"R-H Zhang","year":"2021","unstructured":"Zhang, R.-H., Guo, H.-Y., Deng, H., Li, J. & Quan, Z.-S. Piperazine skeleton in the structural modification of natural products: A review. J. Enzyme. Inhib. Med. Chem. 36(1), 1165\u20131197 (2021).","journal-title":"J. Enzyme. Inhib. Med. Chem."},{"key":"50106_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24589","author":"S Hou","year":"2024","unstructured":"Hou, S. et al. Design, synthesis and antibacterial activity of novel 7H-thiazolo [3, 2-b]-1, 2, 4-triazin-7-one derivatives. Heliyon https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24589\u00a010 (3); (2024).","journal-title":"Heliyon"},{"key":"50106_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111970","volume":"187","author":"H Ahadi","year":"2020","unstructured":"Ahadi, H. & Emami, S. Modification of 7-piperazinylquinolone antibacterials to promising anticancer lead compounds: Synthesis and in vitro studies. Eur. J. Med. Chem. 187, 111970 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"50106_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.133007","volume":"1262","author":"P Yang","year":"2022","unstructured":"Yang, P. et al. Synthesis and in vitro antibacterial activity of N-acylarylhydrazone-ciprofloxacin hybrids as novel fluoroquinolone derivatives. J. Mol. Struct. 1262, 133007 (2022).","journal-title":"J. Mol. Struct."},{"issue":"1","key":"50106_CR32","first-page":"12","volume":"6","author":"EMN Abdelhafez","year":"2023","unstructured":"Abdelhafez, E. M. N., Elgedamy, A. & Shoman, M. Antimicrobial activity of new amide\/thioamides derivatives of ciprofloxacin. J. Adv. Biomed. Pharm. Sci. 6(1), 12\u201315 (2023).","journal-title":"J. Adv. Biomed. Pharm. Sci."},{"issue":"5","key":"50106_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/ph14050399","volume":"14","author":"LH Al-Wahaibi","year":"2021","unstructured":"Al-Wahaibi, L. H. et al. Design, synthesis, and antibacterial screening of some novel heteroaryl-based ciprofloxacin derivatives as DNA gyrase and topoisomerase IV inhibitors. Pharmaceuticals 14 (5), 399 (2021).","journal-title":"Pharmaceuticals"},{"key":"50106_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.135135","volume":"1282","author":"EO Osman","year":"2023","unstructured":"Osman, E. O., Attia, H., Samir, R. & Mahmoud, Z. Design, synthesis, and antibacterial activity of a new series of ciprofloxacin-thiadiazole hybrid. J. Mol. Struct. 1282, 135135 (2023).","journal-title":"J. Mol. Struct."},{"issue":"3","key":"50106_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/antibiotics12030625","volume":"12","author":"H Hryhoriv","year":"2023","unstructured":"Hryhoriv, H., Kovalenko, S. M., Georgiyants, M., Sidorenko, L. & Georgiyants, V. A comprehensive review on chemical synthesis and chemotherapeutic potential of 3-heteroaryl fluoroquinolone hybrids. Antibiotics 12 (3), 625 (2023).","journal-title":"Antibiotics"},{"key":"50106_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.134049","volume":"1271","author":"SA Abdel-Aziz","year":"2023","unstructured":"Abdel-Aziz, S. A. et al. Novel fluoroquinolone hybrids as dual DNA gyrase and urease inhibitors with potential antibacterial activity: Design, synthesis, and biological evaluation. J. Mol. Struct. 1271, 134049 (2023).","journal-title":"J. Mol. Struct."},{"key":"50106_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2024.1493906","volume":"12","author":"LH Al-Wahaibi","year":"2024","unstructured":"Al-Wahaibi, L. H. et al. Synthesis, enzyme inhibition, and docking studies of new Schiff bases of disalicylic acid methylene-based derivatives as dual-target antibacterial agents. Front. Chem. 12, 1493906 (2024).","journal-title":"Front. Chem."},{"key":"50106_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2024.1419242","volume":"12","author":"LH Al-Wahaibi","year":"2024","unstructured":"Al-Wahaibi, L. H. et al. Discovery of new Schiff bases of the disalicylic acid scaffold as DNA gyrase and topoisomerase IV inhibitors endowed with antibacterial properties. Front. Chem. 12, 1419242 (2024).","journal-title":"Front. Chem."},{"issue":"47","key":"50106_CR39","doi-asserted-by":"publisher","first-page":"47261","DOI":"10.1021\/acsomega.4c08365","volume":"9","author":"LH Al-Wahaibi","year":"2024","unstructured":"Al-Wahaibi, L. H. et al. Synthesis and antimicrobial evaluation of new 1, 2, 4-triazolo [1, 5-a] pyrimidine-based derivatives as dual inhibitors of bacterial DNA gyrase and DHFR. ACS Omega 9(47), 47261\u201347273 (2024).","journal-title":"ACS Omega"},{"key":"50106_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2023.134902","volume":"1278","author":"MA Elbastawesy","year":"2023","unstructured":"Elbastawesy, M. A. et al. Design, synthesis and antimicrobial activity of novel quinoline-2-one hybrids as promising DNA gyrase and topoisomerase IV inhibitors. J. Mol. Struct. 1278, 134902 (2023).","journal-title":"J. Mol. Struct."},{"key":"50106_CR41","doi-asserted-by":"crossref","unstructured":"Al-Wahaibi, L. H., Abou-Zied, H. A., Youssif, B. G., Br\u00e4se, S. & Hisham, M. Design, synthesis, apoptotic antiproliferative, and antioxidant activities of a new series of 2-mercaptobenzimidazole\/3-cyanopyridin-2-one hybrids as dual EGFR\/BRAFV600E inhibitors. Bioorg. Chem. 168, 109329. (2025).","DOI":"10.1016\/j.bioorg.2025.109329"},{"issue":"11","key":"50106_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111522","volume":"16","author":"LH Al-Wahaibi","year":"2023","unstructured":"Al-Wahaibi, L. H. et al. Quinazolin-4-one\/3-cyanopyridin-2-one hybrids as dual inhibitors of EGFR and BRAFV600E: Design, synthesis, and antiproliferative activity. Pharmaceuticals 16(11), 1522 (2023).","journal-title":"Pharmaceuticals"},{"issue":"10","key":"50106_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105659","volume":"23","author":"M Marinescu","year":"2022","unstructured":"Marinescu, M. & Popa, C.-V. Pyridine compounds with antimicrobial and antiviral activities. Int. J. Mol. Sci. 23(10), 5659 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"50106_CR44","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s44174-025-00344-y","volume":"4","author":"S Sibi","year":"2026","unstructured":"Sibi, S. et al. Biogenic silver nanoparticle-infused PVA\u2013PEG nanocomposites for food packaging: Physical, anti-microbial, and toxicity evaluation. Biomed. Mater. Devices. 4(1), 1089\u20131101 (2026).","journal-title":"Biomed. Mater. Devices."},{"issue":"1","key":"50106_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/09205063.2025.2523502","volume":"37","author":"R Mohammad Taghi Kashi","year":"2026","unstructured":"Mohammad Taghi Kashi, R., Hekmat, A., Hesami Tackallou, S. & Zali, H. Fabrication of a fibrillar \u03b2-lactoglobulin-Mumijo-nanohydroxyapatite complex for antibacterial and wound healing applications. J. Biomater. Sci. Polym. Ed. 37 (1), 44\u201372 (2026).","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"50106_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104392","volume":"105","author":"M Ramadan","year":"2020","unstructured":"Ramadan, M. et al. Design and synthesis of new pyranoquinolinone heteroannulated to triazolopyrimidine of potential apoptotic antiproliferative activity. Bioorg. Chem. 105, 104392 (2020).","journal-title":"Bioorg. Chem."},{"key":"50106_CR47","doi-asserted-by":"crossref","unstructured":"Alsuwat, M. A. et al. Microbial biofilm formation to mitigate foodborne pathogens strategies and control measures. Indian J. Microbiol. 65,  1\u201316. (2025).","DOI":"10.1007\/s12088-025-01461-4"},{"key":"50106_CR48","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fmicb.2018.00898","volume":"9","author":"S Galie","year":"2018","unstructured":"Galie, S., Garc\u00eda-Guti\u00e9rrez, C., Migu\u00e9lez, E. M., Villar, C. J. & Lomb\u00f3, F. Biofilms in the food industry: Health aspects and control methods. Front. Microbiol. 9, 898 (2018).","journal-title":"Front. Microbiol."},{"issue":"11","key":"50106_CR49","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/j.1600-0463.2010.02681.x","volume":"118","author":"ALS Antunes","year":"2010","unstructured":"Antunes, A. L. S. et al. Application of a feasible method for determination of biofilm antimicrobial susceptibility in staphylococci. APMIS 118(11), 873\u2013877 (2010).","journal-title":"APMIS"},{"issue":"12","key":"50106_CR50","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1128\/AEM.70.12.6951-6956.2004","volume":"70","author":"C Niu","year":"2004","unstructured":"Niu, C. & Gilbert, E. Colorimetric method for identifying plant essential oil components that affect biofilm formation and structure. Appl. Environ. Microbiol. 70 (12), 6951\u20136956 (2004).","journal-title":"Appl. Environ. Microbiol."},{"key":"50106_CR51","doi-asserted-by":"crossref","unstructured":"Mukherjee, T., Sahu, S. S., Pattnaik, A. K., Pradhan, K. K. & Mohanty, S. Navigating in silico drug discovery: A hands-on guide with AutoDock Vina and Discovery Studio, Harnessing Genomic Tools for Crop Improvement, Elsevier2026, pp. 419\u2013446.","DOI":"10.1016\/B978-0-443-29281-1.00004-6"},{"issue":"1","key":"50106_CR52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00044-024-03325-w","volume":"34","author":"MF Mohamed","year":"2025","unstructured":"Mohamed, M. F., Soliman, A. M., Alshazly, O., Nafady, A. & Soomro, R. A. Design, synthesis, molecular docking, and antibacterial activity of novel amide-linked tetrahydrobenzothienopyrimidinone derivatives as potential DNA gyrase and topoisomerase IV inhibitors. Med. Chem. Res. 34(1), 172\u2013182 (2025).","journal-title":"Med. Chem. Res."},{"key":"50106_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.commatsci.2025.114013","volume":"257","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Molecular dynamics simulation of real paraffin wax melting points based on OPLS-AA force field parameter optimization. Comput. Mater. Sci. 257, 114013 (2025).","journal-title":"Comput. Mater. Sci."},{"issue":"1","key":"50106_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/0113816128373506250414160220","volume":"32","author":"MA Hossain","year":"2026","unstructured":"Hossain, M. A. et al. Binding interaction and stability analysis of Quercetin and its derivatives as potential inhibitors of Triple Negative Breast Cancer (TNBC) against PARP1 protein: An in-silico study. Curr. Pharm. Des. 32(1), 52\u201371 (2026).","journal-title":"Curr. Pharm. Des."},{"issue":"08","key":"50106_CR55","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1142\/S2737416525500929","volume":"25","author":"A Preethi","year":"2026","unstructured":"Preethi, A., Natarajan, S. & Anbarasu, A. Marmin-derivatives as promising inhibitors of cysteine synthases from Mycobacterium tuberculosis: An in silico approach. J. Comput. Biophys. Chem. 25(08), 1255\u20131272 (2026).","journal-title":"J. Comput. Biophys. Chem."},{"issue":"1","key":"50106_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202506089","volume":"11","author":"B Datta","year":"2026","unstructured":"Datta, B., Roy, S., Sakugawa, Z., Dasgupta, B. & Dasgupta, S. Structure-based in silico assessment of strategically designed quinazolinone derivatives for multi\u2010target Alzheimer\u2019s disease: From ADMET to molecular dynamics. ChemistrySelect 11(1), e06089 (2026).","journal-title":"ChemistrySelect"},{"issue":"02","key":"50106_CR57","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1142\/S2737416525500474","volume":"25","author":"MA Babaker","year":"2026","unstructured":"Babaker, M. A. et al. Discovery of novel potential binders targeting Norovirus 3CL protease: A machine learning and molecular dynamics approach. J. Comput. Biophys. Chem. 25(02), 257\u2013275 (2026).","journal-title":"J. Comput. Biophys. Chem."},{"issue":"8","key":"50106_CR58","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s00044-019-02372-y","volume":"28","author":"HA Aziz","year":"2019","unstructured":"Aziz, H. A. et al. New fluoroquinolones\/nitric oxide donor hybrids: Design, synthesis and antitubercular activity. Med. Chem. Res. 28(8), 1272\u20131283 (2019).","journal-title":"Med. Chem. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50106-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50106-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50106-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:02:24Z","timestamp":1777568544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50106-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50106"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50106-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13911"}}